Skip to main
  1. Stocks
  2. Beta Bionics Inc
  3. Forecast
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics is attractive because its iLet continues to gain share through a differentiated, easy-to-use closed-loop insulin delivery system, and the company has already delivered year-one public-company success with financial upside and roughly 10% NRx share. The outlook is further strengthened by raised full-year revenue expectations to $124-126M, reaffirmed key operating metrics, and a pipeline that includes Mint and 3D Intelligence, which should broaden adoption and support revenue outperformance as commercialization progresses. Although Mint’s launch may temporarily shift some revenue into 2027 and pressure near-term gross margin, the larger patch-pump opportunity, expected capacity for 1.5M+ units in 2027, and a path toward profitability support a constructive long-term fundamental view.

Bears say

Beta Bionics is facing a fundamentally challenging setup because gross margin of 57.3% missed expectations as lower-margin DME supplies and stocking dynamics offset the revenue mix from the higher-margin iLet Bionic Pancreas. Regulatory execution risk is also elevated after the company withdrew its 510(k) submission for the 3D Intelligence Algorithm at the FDA’s request, pushing revised submission to mid-Q4 2026 and launch expectations to mid-2027. Beyond that, the bear case is reinforced by uncertain market share gains, potential pressure on pharmacy-channel penetration, possible CMS headwinds, and the risk that additional capital needs could dilute shareholders.

BBNX has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

BBNX Analyst Forecast & Price Prediction

Get the latest BBNX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BBNX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 12 analysts, BBNX has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


BBNX Analyst Forecast & Price Prediction

Get the latest BBNX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BBNX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BBNX stock data and trends